Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis, drug candidate TOL2 has achieved several positive preclinical results.
VelociSuite technologies facilitate rapid generation of optimized antibodies allowing for cell line production and large-scale bioreactor manufacturing
Mike Grippo will serve as senior vice president, Strategy and Corporate Development, and Julien Meissonnier as vice president and chief scientific officer
JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.
Clinical leaders discuss bringing together disparate processes and systems for improved collaboration and more efficient trial execution at Veeva R&D Summit
Online ExclusivesJim Reilly, vice president of clinical strategy at Veeva Systems10.18.19